BioLineRx Reports Q3 2016 Financial Results

- November 22nd, 2016

BioLineRx today announced its financial results for the third quarter of 2016, which ended on September 30, 2016.

BioLineRx (NASDAQ:BLRX), a biopharmaceutical company that focuses on in-licensing, today announced its financial results for the third quarter of 2016, which ended on September 30, 2016.
According to the press release:

“The Company’s operating loss for the three months ended September 30, 2016amounted to $4.5 million, compared with an operating loss of $3.6 million for the corresponding 2015 period. The Company’s operating loss for the nine months ended September 30, 2016 amounted to $12.1 million, similar to the comparable period in 2015.”

CEO Philip A. Serlin said the following:

“We are excited about our prospects ahead and are focused on achieving our expected milestones for 2017 and beyond. With $39 million of cash on hand, we remain well positioned to carry out our operational plans for the next few year.”

Read the full press release here.

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply